increasing prevalence of diabetes worldwide is a major driver of the DFU biologics market, as diabetic patients face a significantly higher risk of chronic, non-healing wounds due to poor circulation, neuropathy, and impaired immune response. Innovations such as stem cell-based therapies, amniotic membrane grafts, and bioengineered skin substitutes are improving wound healing efficiency and reducing recovery times propel the growth of the market.
read more..